Table 3 Pooled adverse events of endostatin combined with radiotherapy or chemoradiotherapy

Radiation pneumonitis

All

55.9 (31.4–77.9)

50.7 (20.9–80.0)

64.1 (27.3–89.4)

≥3

10.9 (5.4–20.8)

11.9 (4.5–27.9)

9.4 (3.3–24.0)

Radiation esophagitis

All

77.4 (69.4–83.7)

89.7 (83.1–93.9)

55.5 (40.9–69.3)

≥3

11.6 (7.6–17.5)

12.2 (7.6–19.0)

9.4 (3.3–24.0)

Neutropenia

All

76.5 (55.6–89.4)

85.7 (78.5–90.7)

25.1 (71.6–89.9)

≥3

27.8 (14.3–47.0)

40.1 (30.3–50.8)

2.1 (0.3–13.7)

Leukopenia

All

84.5 (49.7–96.8)

91.8 (78.2–97.2)

40

≥3

35.5 (18.5–57.7)

43.4 (27.2–61.2)

0

Anemia

All

54.7 (34.7–73.3)

70.5 (62.1–77.6)

28.9 (17.6–43.6)

≥3

10.5 (6.2–17.2)

12.3 (7.6–19.1)

2.1 (0.3–13.7)

Thrombocytopenia

All

46.0 (23.2–59.3)

52.5 (34.2–70.2)

35.7 (23.1–50.7)

≥3

6.9 (2.4–18.3)

10.1 (3.3–26.7)

2.1 (0.3–13.7)

Nausea/vomiting

All

48.2 (32.5–64.2)

54.1 (38.7–68.7)

40

≥3

5.8 (2.8–11.6)

6.3 (3.0–12.9)

0

Arrhythmia

All

25.7 (9.5–52.7)

37

15

≥3

0

0

0

Fatigue

All

58.0 (39.3–74.7)

67.4 (56.7–76.5)

40

≥3

2.6 (0.7–8.7)

2.7 (0.7–1.3)

0

Hemorrhage

All

NR

15.2 (9.0–24.5)

NR

≥3

NR

1.8 (0.4–8.3)

NR

Hypertension

All

NR

2

NR

≥3

NR

0

NR